Kazia’s Breakthrough in Brain Cancer Therapy: Phase I Trial Shows Promising Results
In a groundbreaking development, Kazia Therapeutics Limited (NASDAQ: KZIA), an esteemed Australian biotechnology company, has revealed the remarkable outcome of its Phase I clinical trial for brain cancer therapy. The trial, which focused on evaluating the efficacy of paxalisib, an oral PI3K/mTOR dual inhibitor, in combination with radiation therapy, has concluded earlier than expected due to overwhelmingly positive safety and clinical response data.
The initial phase of the trial successfully determined the maximum tolerated dose of paxalisib in conjunction with radiation therapy, demonstrating encouraging clinical activity among nine evaluated patients. Subsequently, the expansion cohort, designed to further investigate the treatment’s safety and effectiveness, witnessed a continuation of promising clinical responses among up to 12 additional patients. With the primary endpoint of the study met, the investigators have expressed profound satisfaction with the trial’s progression and outcomes.
Dr. John Friend, the esteemed CEO of Kazia, hailed the trial’s findings as a significant stride forward in combating brain cancer. He unveiled plans to initiate discussions with the FDA to seek guidance for a pivotal registration study, marking a pivotal step towards advancing paxalisib’s development and eventual accessibility to patients in need.
The activation of the PI3K pathway, a prevalent occurrence in brain metastases, has long been associated with tumor resistance to radiotherapy. The integration of paxalisib with radiotherapy holds immense promise in enhancing disease control and potentially revolutionizing existing treatment modalities. The comprehensive findings from the trial’s second phase are slated for presentation at an upcoming global scientific conference, underscoring Kazia’s commitment to transparency and scientific rigor.
In a significant development last year, paxalisib garnered Fast Track Designation from the FDA for its efficacy in treating solid tumor brain metastases with PI3K pathway mutations in conjunction with radiation therapy. Given that approximately 200,000 cancer patients in the United States alone are diagnosed with brain metastases annually, coupled with the variable efficacy of existing radiotherapy treatments, the imperative for innovative therapeutic interventions cannot be overstated.
Moreover, Kazia’s robust pipeline includes EVT801, a potent VEGFR3 inhibitor, with preliminary data anticipated in CY2024. The continued evaluation of paxalisib across multiple clinical trials for various forms of brain cancer underscores Kazia’s unwavering commitment to pioneering research and patient-centric healthcare solutions.
This report is sourced from an official press release statement issued by Kazia Therapeutics Limited, highlighting a momentous breakthrough in the realm of brain cancer therapy that promises renewed hope for countless patients worldwide.
For More Please Visit: Newsgage.com
Connect With Us: Click Here Connect With Us On Whatsapp